Meet the Advisory Board
Dr. Aditya Bardia
Aditya Bardia, M.D., MPH is a board-certified medical oncologist, an Attending Physician at Massachusetts General Hospital (MGH) Cancer Center, and Assistant Professor of Medicine at Harvard Medical School. As the Director of Precision Oncology Program at the MGH Center for Breast Cancer, Dr. Bardia has led the clinical development of the newly-approved antibody drug conjugate (ADC), Sacituzumab Govitecan, and is working on an investigational oral estrogen receptor degrader (SERD) for metastatic breast cancer patients. Dr. Bardia is especially interested in optimal biological drug dosage adaptations to maximize quality of life for individual patients while maintaining treatment efficacy. Dr. Bardia has received several research awards: the outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.
Dr. Mark Burkard
Mark Burkard, M.D., PhD, is a professor of Medicine and Oncology in the University of Wisconsin (UW) School of Medicine and Public Health, and is Associate Director for Genomics and Precision Medicine in the UW Carbone Cancer Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester, after which he trained in internal medicine at New York Hospital/Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. Dr. Burkard has received three UW Health Patient Experience Physician Champion Awards, a Komen Madison Award for Commitment to Research and Treatment on Breast Cancer, a UW School of Medicine and Public Health Dean’s Teaching Award, and a UW Department of Medicine Page-Grossman Professionalism Award. Dr. Burkard maintains a special interest in ascertaining why some metastatic breast cancer patients fare exceptionally well despite their terminal prognosis, and is the principal investigator of an investigational “Outliers” study to explore the physiological and lifestyle factors contributing to MBC patients’ durable treatment response and remarkable longevity.
Dr. Kevin Kalinsky
Kevin Kalinsky, M.D., M.S. is Acting Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, serving as the director of the Glenn Family Breast Center at Winship. Dr. Kalinsky received his M.D. from the Medical University of South Carolina and subsequently completed his Internal Medicine internship, residency, and Hematology/Oncology fellowship at Tufts Medical Center. Dr. Kalinsky trained as a breast cancer clinical research fellow at Massachusetts General Hospital and obtained an advanced oncology fellowship in breast cancer at Memorial Sloan-Kettering Cancer Center. Dr. Kalinsky currently cares for patients diagnosed with breast cancer and teaches on the Breast Oncology service, and is a passionate researcher involved in the development of early phase clinical trials to assess novel therapeutic agents in breast cancer. A recipient of the Ewig Clinical Scholar Teaching Award at Columbia, the SWOG/Hope Foundation Impact Award, and the One Race One Mission-Physician of Impact Award by Komen Greater NYC.
Dr. Hope Rugo
Hope Rugo, M.D. is a hematologist-oncologist specializing in breast cancer treatment. Dr. Rugo graduated from the University of Pennsylvania School of Medicine and completed a residency in internal medicine and primary care, followed by a fellowship in hematology and oncology, at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University, after which she joined the faculty at UCSF in the Division of Hematology and Oncology. As Director of the UCSF Breast Oncology Clinical Trials Program, Dr. Rugo is the principal investigator for several clinical trials of potential new therapies. a founding member of the Breast Cancer Research Consortium, and an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians and regularly lectures locally, nationally, and internationally on subjects relating to the treatment of breast cancer. She has received the Bank of America Gianini Foundation Award, a UCSF Clinical Cancer Center Investigator Research Program intra-mural award, and has been honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.
Dr. Maryam Lustberg
Maryam Lustberg, M.D., the Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She received her Medical Degree at the University of Maryland School of Medicine in 2003. Dr. Lustberg previously served as the Medical Director of Supportive Care at Ohio State's Comprehensive Cancer Center and President-Elect of the Multinational Association of Supportive Care in Cancer. She is also an associate editor for the peer-reviewed medical journal covering oncology nursing with respect to cancer survivors called Journal of Cancer Survivorship, and much of her research has focused on physicians’ and patients’ perspectives regarding cancer survivorship care, prevention of chemotherapy-induced peripheral neuropathy, and early detection of chemotherapy induced cardiotoxicity in breast cancer survivors. In 2020, Dr. Lustberg became the President Elect of the Multinational Association of Supportive Care in Cancer.[